In percutaneous coronary intervention (PCI), the concept of securing metal free angioplasty without leaving behind a permanent foreign body is highly attractive to patients and physicians and promises several advantages. However, target lesion failure and device thrombosis were important concerns with first-generation Bioresorbable scaffolds (BRS) leading to low rates of adoption in clinical practice (1-12). New iterations, incorporating improvements such as a smaller strut thickness have been proposed and evaluated in early investigations. However, it remains unclear whether these modifications are sufficient to achieve outcomes comparable to those of metallic drug-eluting stents (DES) while preserving the benefits of resorption (10-12).
Author Sub-editor: Dr Joshua Rowland Dr Joshua Rowland is a cardiology registrar working in the North West Deanery. He graduated from the University of Manchester
Author Sub-editor: Dr Atmadeep Banerjee Dr Atmadeep Banerjee is an ST4 Cardiology Registrar in the Kent, Surrey and Sussex deanery. He graduated from Calcutta National
Authors Heartbeat Sub-Editor: Sandeep Singh Dr Sandeep Singh is a Cardiology Clinical Fellow at Nottingham University Hospitals NHS Trust. After graduating from India, he completed
Authors Heartbeat Sub-Editor: Khin Kay Kay Kyaw I am currently working as cardiology specialist registrar ST6 at southwest peninsula region while also working as an